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In this article, evidence is reviewed suggesting that the outcome of cancer immunotherapy depends on pre-treatment
immune parameters of a patient. The results described in the article show that immunotherapy may prolong survival in
certain subgroups of cancer patients, while in other subgroups a cancer-promoting effect of this treatment modality
cannot be excluded.
Cancer immunotherapy is a rapidly
expanding area of research and clinical
practice. Cytokines, monoclonal antibodies,
vaccines and adoptive cell immunotherapy
are increasingly being studied in trials and
used in clinics. There is one aspect,
however, which has been largely ignored
in cancer immunotherapy studies: hetero-
geneity of survival rates among untreated
patients. If this is taken into account, two
questions remain to be answered. First,
what is the role of immunological factors
in determining the survival of untreated
cancer patients? Second, do patients with
good immunological prognostic factors
benefit from immunotherapy?
Regarding the clinical outcome, renal
cell carcinoma (RCC) is one of the most
heterogeneous of adult malignancies. In
general, outcome of patients with meta-
static RCC is poor with the median
survival of approximately 1 y. However,
some primary tumors and metastases of
RCC, especially pulmonary parenchymal
lesions, may have periods with little or no
growth during many months.
1 A subset
(from 10% to 20%) of patients with
metastatic RCC survive 5 or more years.
1,2
In the late nineties, our group has
studied the prognostic significance of
peripheral blood lymphocyte subsets in
advanced RCC patients using flow
cytometry. We found remarkable differ-
ences in overall survival of advanced RCC
patients based on peripheral blood levels
of CD8
highCD57
+ lymphocytes.
3 In our
analysis, the median overall survival of
patients with , 30% CD8
highCD57
+
lymphocytes in the CD8
+ subset was
23.5 mo (the “relatively good prognosis
group”), whereas the median overall
survival of patients with $ 30%
CD8
highCD57
+ lymphocytes in the CD8
+
subset was only 6 mo (the “bad prognosis
group”). High expression of CD8 antigen
distinguishes CD8
+ T cells from CD8
+
NK cells that have low expression of
CD8.
4 Expression of CD57 antigen on T
lymphocytes is regarded as a marker of
immune deficiency in patients with auto-
immune disease, infectious diseases and
cancer.
5 Thus, differences in survival
among untreated advanced RCC patients
may depend on immunological factors,
i.e., levels of CD8
highCD57
+ lymphocytes.
During 1995–1999, interferon-a (IFNa)
was just being introduced in Lithuania,
and no strict guidelines toward its use for
treatment of metastatic RCC were avail-
able. Due to considerable variability in
approach to treatment of metastatic RCC
patients in Lithuania, we were able to
select subgroups of patients treated and
non-treated with IFNa. Thus, we had the
opportunity to perform a retrospective
analysis of the predictive significance of
peripheral blood lymphocyte subsets for
treatment with IFNa of patients with
advanced RCC. Treatment with IFNa
significantly increased the median overall
survival of the “bad prognosis group”
RCC patients (from 6 to 18.5 mo). In
contrast, a trend toward decreased median
overall survival was observed in the
“relatively good prognosis group” after
treatment with IFNa (13.6 mo of IFNa-
treated patients vs. 23.5 mo of patients
non-treated with IFNa).
3 These our
results suggest, that immunotherapy with
IFNa may benefit patients with poor
immunological prognostic factors, whereas
this treatment may even be harmful for
patients with good immunological prog-
nostic factors.
Thousands of melanoma patients have
been enrolled in adjuvant IFNa trials
with the aim to determine a statistically
significant improvement in survival. In a
recent systematic review and meta-analysis
of 14 randomized controlled trials includ-
ing a total of 8,122 patients, it was shown
that treatment with IFNa statistically
significantly improves the overall survival
of high-risk melanoma patients with a risk
reduction of 11%.
6 However, it has to be
taken into account that 60% of patients
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with stages II-III cutaneous melanoma
survive 5 y without any treatment.
6 Can
these patients benefit from adjuvant IFNa
therapy?
Several published reports show that
longer survival of melanoma patients is
associated with increased levels of CD8
+
CD57
+ T lymphocytes in peripheral
blood (for a review see ref. 7). However,
to our knowledge, CD8
+CD57
+ T lym-
phocyte levels have never been measured
in trials of adjuvant IFNa in high-risk
melanoma. Our results have shown that
pre-treatment levels of peripheral blood
CD8
highCD57
+ lymphocytes remarkably
predict the survival of high-risk melanoma
patients after treatment with IFNa.
Median overall survival of patients with
, 23% CD8
highCD57
+ lymphocytes in
the CD8
+ subset was not reached at a
median follow-up of 24.6 mo, whereas
median overall survival of patients with
. 23% CD8
highCD57
+ lymphocytes was
only 14.2 mo.
8 The detrimental effect of
adjuvant IFNa in the latter group of
patients cannot be excluded.
In conclusion, our results reviewed in
this article and the results by other authors
(for a review see ref. 9) strongly suggest
that the outcome of immunotherapy
depends on pre-treatment immune para-
meters of a cancer patient. Immuno-
therapy may prolong survival in certain
subgroups of patients, most likely in those
with poor immunological prognostic fac-
tors. However, immunotherapy should be
administered cautiously to patients with
good immunological prognostic factors,
because a cancer-promoting effect of this
treatment modality cannot be excluded
(for a review see ref. 7). Schematic outline
of the implications of the data reviewed in
this article is shown in Figure1.
CD8
+ T lymphocytes are well-
documented effectors of tumor immu-
nity. There is ample evidence on the
prognostic significance of CD8
+ lympho-
cytes within a tumor or in peripheral
blood of cancer patients.
9,10 Thus, num-
bers and maybe functional characteristics
of CD8
+ T lymphocytes or their subsets
may reflect the immunologic reactivity
of the cancer patient and predict benefi-
cial or harmful effects of immunotherapy.
Our results support the predictive signifi-
cance of peripheral blood CD8
highCD57
+
lymphocyte levels, but more research is
needed.
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Figure1. Schematic outline of the implications of the data reviewed in this article. Depending on
pre-treatment immune parameters, immunotherapy may prolong survival in one subgroup of
patients, while in another subgroup survival may be decreased compared with non-treated
patients. As a result, the total effect of the therapeutic intervention may be nullified.
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